Dalbavancin: new single-dose antibiotic for acute skin infections

Xydalba (dalbavancin) is the first antibiotic to provide a full course of iv therapy for acute bacterial skin and skin structure infections in a single dose.

Dalbavancin is available as a powder for concentrate to be made up into a solution for infusion providing 20mg per ml.

The recommended adult dose is a single iv infusion of 1.5g given over 30 minutes or a single infusion of 1g followed by a 500mg dose one week later. Dalbavancin is not recommended in children and adolescents under 18 years of age.

Dalbavancin is a bactericidal lipoglycopeptide which demonstrates in vitro activity against Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus.

The most commonly reported adverse effects with dalbavancin in clinical trials were headache, nausea and diarrhoea.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Early emollient use does not prevent eczema in children

Early emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...